Evaluation of histopathological heterogeneity of colorectal cancer liver metastasis sites after preoperative chemotherapy

被引:0
作者
Matsuhashi, Nobuhisa [1 ]
Tomita, Hiroyuki [2 ]
Tanaka, Hidenori [1 ]
Iwata, Yoshinori [1 ]
Matsui, Satoshi [1 ]
Imai, Hisashi [1 ]
Fukada, Masahiro [1 ]
Mizutani, Chika [1 ]
Takahashi, Takao [1 ]
Yasufuku, Itaru [1 ]
Suetsugu, Tomonari [1 ]
Mori, Ryutaro [1 ]
Tanaka, Yoshihiro [1 ]
Okumura, Naoki [1 ]
Futamura, Manabu [1 ]
Yoshida, Kazuhiro [1 ]
机构
[1] Gifu Univ, Grad Sch Med, Dept Surg Oncol, Gifu, Gifu 5011194, Japan
[2] Gifu Univ, Grad Sch Med, Dept Tumor Pathol, Gifu, Gifu 5011194, Japan
关键词
histopathological; heterogeneity; colorectal cancer; liver; metastasis; PATHOLOGICAL RESPONSE; 1ST-LINE TREATMENT; BEVACIZUMAB; OXALIPLATIN; CETUXIMAB; SURVIVAL; PLUS; COMBINATION; PANITUMUMAB; MFOLFOX6;
D O I
10.3892/mco.2022.2494
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with liver metastases from colorectal cancer (CRI,Ms) frequently receive chemotherapy prior to liver resection. Histopathological assessment of the resected specimen can evaluate the response to chemotherapy. The present study analyzed the association between histopathological changes in the primary site and liver metastases. The present study comprised 45 patients with resectable CRLMs at the Surgical Oncology Department of Gifu University School of Medicine (Gifu, Japan) between January 2006 and August 2015. The study included 24 men and 21 women. The primary colonic tumor was located in the right side in 13 (28.9%) patients and the left side in 32 (71.9%) patients. The present study evaluated patients with metastatic colorectal cancer (31/45) after excluding those in whom histopathological heterogeneity between the primary and liver metastasis changed to grade 3 after chemotherapy. The group that underwent hepatectomy after chemotherapy (n=25) was compared with the group that underwent hepatectomy alone (n=6). In 16 (53.3%) out of 25 patients, histopathological heterogeneity of the liver metastasis was lost (P=0.04). In conclusion, chemotherapy appeared to change histopathological heterogeneity. The present study suggested that the histopathological change of intratumoral heterogeneity is reflected by the response to chemotherapy.
引用
收藏
页数:6
相关论文
共 24 条
[1]  
[Anonymous], CANC STAT JAPAN 2018
[2]   Systematic Review of Randomized and Nonrandomized Trials of the Clinical Response and Outcomes of Neoadjuvant Systemic Chemotherapy for Resectable Colorectal Liver Metastases [J].
Chua, Terence C. ;
Saxena, Akshat ;
Liauw, Winston ;
Kokandi, Adel ;
Morris, David L. .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (02) :492-501
[3]   Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases [J].
Chun, Yun Shin ;
Vauthey, Jean-Nicolas ;
Boonsirikamchai, Piyaporn ;
Maru, Dipen M. ;
Kopetz, Scott ;
Palavecino, Martin ;
Curley, Steven A. ;
Abdalla, Eddie K. ;
Kaur, Harmeet ;
Charnsangavej, Chusilp ;
Loyer, Evelyne M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (21) :2338-2344
[4]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[5]   Histopathologic patterns as markers of prognosis in patients undergoing hepatectomy for colorectal cancer liver metastases - Pushing growth as an independent risk factor for decreased survival [J].
Falcao, Daniela ;
Alexandrino, Henrique ;
Oliveira, Rui Caetano ;
Martins, Joao ;
Ferreira, Luis ;
Martins, Ricardo ;
Serodio, Marco ;
Martins, Monica ;
Tralhaoa, Jose Guilherme ;
Cipriano, Maria Augusta ;
Castro e Sousa, Francisco .
EJSO, 2018, 44 (08) :1212-1219
[6]   Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial [J].
Folprecht, Gunnar ;
Gruenberger, Thomas ;
Bechstein, Wolf O. ;
Raab, Hans-Rudolf ;
Lordick, Florian ;
Hartmann, Joerg T. ;
Lang, Hauke ;
Frilling, Andrea ;
Stoehlmacher, Jan ;
Weitz, Juergen ;
Konopke, Ralf ;
Stroszczynski, Christian ;
Liersch, Torsten ;
Ockert, Detlev ;
Herrmann, Thomas ;
Goekkurt, Eray ;
Parisi, Fabio ;
Koehne, Claus-Henning .
LANCET ONCOLOGY, 2010, 11 (01) :38-47
[7]   Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study [J].
Gruenberger, Birgit ;
Schueller, Johannes ;
Heubrandtner, Ute ;
Wrba, Fritz ;
Tamandl, Dietmar ;
Kaczirek, Klaus ;
Roka, Rudolf ;
Pircher, Sandra Freimann ;
Gruenberger, Thomas .
LANCET ONCOLOGY, 2010, 11 (12) :1142-1148
[8]   Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer [J].
Gruenberger, Brigit ;
Tamandl, Dietmar ;
Schueller, Johannes ;
Scheithauer, Werner ;
Zielinski, Christoph ;
Herbst, Friedrich ;
Gruenberger, Thomas .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1830-1835
[9]   Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival [J].
Gruenberger, T. ;
Arnold, D. ;
Rubbia-Brandt, L. .
SURGICAL ONCOLOGY-OXFORD, 2012, 21 (04) :309-315
[10]   FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial [J].
Heinemann, Volker ;
von Weikersthal, Ludwig Fischer ;
Decker, Thomas ;
Kiani, Alexander ;
Vehling-Kaiser, Ursula ;
Al-Batran, Salah-Eddin ;
Heintges, Tobias ;
Lerchenmueller, Christian ;
Kahl, Christoph ;
Seipelt, Gernot ;
Kullmann, Frank ;
Stauch, Martina ;
Scheithauer, Werner ;
Hielscher, Joerg ;
Scholz, Michael ;
Mueller, Sebastian ;
Link, Hartmut ;
Niederle, Norbert ;
Rost, Andreas ;
Hoeffkes, Heinz-Gert ;
Moehler, Markus ;
Lindig, Reinhard U. ;
Modest, Dominik P. ;
Rossius, Lisa ;
Kirchner, Thomas ;
Jung, Andreas ;
Stintzing, Sebastian .
LANCET ONCOLOGY, 2014, 15 (10) :1065-1075